Understanding ICH Q11—FDA's Guidance on the Development and Manufacture of Drug Substances - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Understanding ICH Q11—FDA's Guidance on the Development and Manufacture of Drug Substances
The author provides a review of FDA's guidance document, Guidance for Industry: Q11 Development and Manufacture of Drug Substances, and its relation to the International Conference on Harmonization's Q11 document and its application to the industry.


Pharmaceutical Technology
Volume 37, Issue 5, pp. 64-68

Process validation

It is a fundamental expectation that manufacturers of drug substances validate their processes as appropriate. From an ICH perspective, process validation is "the documented evidence that the process, operated within established parameters, can perform effectively and reproducibly to produce a drug substance or intermediate meeting its predetermined specifications and quality attributes" (1). The targeted result of process validation is the collection of scientific evidence to support claims that a process is stable and capable of providing a predictable and repeatable output. Validation activities are expected to be pursued from initial drug-substance design through to the processes employed for manufacturing, including packaging.

Employing the CTD format for information submission

Drug substance quality, safety, and efficacy data must be compiled and placed into the Common Technical Document (CTD) format. Additional guidance pertaining to FDA's requirement for electronic submissions can be found in Guidance for Industry: Providing Regulatory Submissions In Electronic Format—Certain Human Pharmaceutical Product Applications And Related Submissions Using the eCTD Specifications (11). According to ICH M4, the CTD is broken down into four modules (note: the first bulleted point is not part of the CTD):
  • Module 1—Region-Specific Information
  • Module 2—Quality and overall summary and clinical overview and summary
  • Module 3—Quality
  • Module 4—Nonclinical study reports
  • Module 5—Clinical-study reports (12-16).

According to FDA's guidance, organization of the electronic submission should be in folders that align with Modules 2 through 5 (11).

Lifecycle management

ICH Q11 requires the manufacturers of drug substances to implement continuous-improvement practices throughout the entire lifecycle of each drug substance. The employment of science and risk-based approaches for each lifecycle stage is a fundamental expectation of the ICH Q11 Guidance Document (1). A true lifecycle will encompass all stages from initial design and development, validation of processes, manufacturing, commercialization, and end-of-life. Manufacturers are expected to evaluate manufacturing processes, the control strategy, and ongoing product safety and efficacy. All knowledge garnered during these evaluations, including knowledge gained from post-market surveillance activities, should be used to drive ongoing product improvement. Additionally, information collected should include:

  • Process-development activities
  • Technology-transfer activities
  • Process-validation studies
  • Change-management activities (1).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here